Alpha 2.0
Login Register
» Authors » Mami Hirakawa

Mami Hirakawa

Explore the profile of Mami Hirakawa including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 92
Followers 0
Related Specialties
Oncology
Neurology
Psychology
Top 10 Co-Authors
Yoshiki Horie
Naoki Izawa
Takashi Tsuda
Takuro Mizukami
Takashi Ogura
Takako Eguchi Nakajima
Hiroyuki Arai
Yu Sunakawa
Toshitaka Nabeshima
Kuniaki Saito
Published In
Behav Brain Res
Mol Clin Oncol
World J Gastroenterol
Oncotarget
Neurochem Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Hamano J, Higashibata T, Kessoku T, Kajiura S, Hirakawa M, Oyamada S, et al.
J Clin Oncol . 2024 Sep; 42(35):4206-4217. PMID: 39255425
Purpose: Opioid-induced constipation is the most frequent and non-self-limiting adverse effect of opioid analgesia, reducing adherence and interfering with pain relief. This clinical trial aimed to clarify the preventive effect...
2.
Deficiency of kynurenine 3-monooxygenase exacerbates impairment of prepulse inhibition induced by phencyclidine
Kubota H, Kunisawa K, Niijima M, Hirakawa M, Mori Y, Hasegawa M, et al.
Biochem Biophys Res Commun . 2022 Sep; 629:142-151. PMID: 36116377
Phencyclidine (PCP) causes mental symptoms that closely resemble schizophrenia through the inhibition of the glutamatergic system. The kynurenine (KYN) pathway (KP) generates metabolites that modulate glutamatergic systems such as kynurenic...
3.
Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol
Higashibata T, Hamano J, Kessoku T, Kajiura S, Hirakawa M, Horie Y, et al.
Contemp Clin Trials Commun . 2022 Aug; 29:100967. PMID: 35967517
Background: It is unclear which laxatives are appropriate to prevent opioid-induced constipation (OIC). This study will evaluate whether prophylactic use of naldemedine prevents OIC in patients with cancer who start...
4.
Loureirin C and Xanthoceraside Prevent Abnormal Behaviors Associated with Downregulation of Brain Derived Neurotrophic Factor and AKT/mTOR/CREB Signaling in the Prefrontal Cortex Induced by Chronic Corticosterone Exposure in Mice
Yang Y, Mouri A, Lu Q, Kunisawa K, Kubota H, Hasegawa M, et al.
Neurochem Res . 2022 Jul; 47(9):2865-2879. PMID: 35871433
Brain derived neurotrophic factor (BDNF) is one of the most abundant neurotrophic factors, and its deficits are involved in the pathogenesis of major depressive disorders (MDD). Loureirin C (Lou C)...
5.
Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment
Mizukami T, Hamaji K, Onuki R, Yokomizo A, Nagashima Y, Takeda H, et al.
Nutr Cancer . 2021 Mar; 74(2):539-545. PMID: 33754895
Limited information is available regarding the impact of body weight loss (BWL) in patients with advanced gastric cancer (AGC) who receive second-line chemotherapy. We retrospectively reviewed data for consecutive AGC...
6.
Kynurenine 3-monooxygenase deficiency induces depression-like behavior via enhanced antagonism of α7 nicotinic acetylcholine receptors by kynurenic acid
Mori Y, Mouri A, Kunisawa K, Hirakawa M, Kubota H, Kosuge A, et al.
Behav Brain Res . 2021 Feb; 405:113191. PMID: 33607168
Tryptophan (TRP) is metabolized via the kynurenine (KYN) pathway, which is related to the pathogenesis of major depressive disorder (MDD). Kynurenine 3-monooxygenase (KMO) is a pivotal enzyme in the metabolism...
7.
Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy
Taniyama T, Tsuda T, Miyakawa K, Arai H, Doi A, Hirakawa M, et al.
Esophagus . 2019 Sep; 17(1):67-73. PMID: 31506805
Background And Aim: Fistula is one of the known complications of T4 esophageal cancer (T4-EC). The standard treatment for T4-EC is chemoradiotherapy, but detailed data about fistula resulting from chemoradiotherapy...
8.
Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression
Lu Q, Mouri A, Yang Y, Kunisawa K, Teshigawara T, Hirakawa M, et al.
Behav Brain Res . 2019 Jul; 372:112053. PMID: 31288060
Accumulating evidence shows that stressful events evoke molecular alterations in the brain, considered a pathology in major depressive disorder (MDD). However, the abnormalities of neurotransmissions as well as intracellular signaling...
9.
Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer
Izawa N, Sunakawa Y, Doi A, Arai H, Horie Y, Hirakawa M, et al.
Oncology . 2019 Jun; 97(2):94-101. PMID: 31195391
Objectives: This study aimed to evaluate whether a decrease of computed tomography (CT) value for tumors serves as a predictive marker in patients with advanced gastric cancer (aGC) who have...
10.
Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer
Nakajima T, Boku N, Doi A, Arai H, Mizukami T, Horie Y, et al.
Invest New Drugs . 2019 Apr; 38(2):410-418. PMID: 31020609
KRAS wild-type colorectal cancers initially responsive to anti-endothelial growth factor receptor (EGFR) antibodies [cetuximab (Cetu)/panitumumab (Pani)] develop acquired resistance. Overexpression of EGFR ligands such as heparin-binding EGF-like growth factor (HB-EGF)...